Nektar: NKTR-255 for Hematological Malignancies - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if a study drug called NKTR-255 alone or in combination with daratumumab or rituximab is a safe and effective treatment for multiple myeloma or non-Hodgkin lymphoma when it is combined with other drugs.

What is the Condition Being Studied?

Relapsed/Refractory Multiple Myeloma and non-Hodgkin lymphoma

Who Can Participate in the Study?

Adults ages 18+ who:
- Have multiple myeloma or non-Hodgkins lymphoma that is not responding to therapy; OR
- Have multiple myeloma or non-Hodgkins lymphoma that has come back after previous therapy

For more information about who can join this study, please contact the study team 919-668-0613.

Age Group

What is Involved?

There are 2 parts to this study. In Part 1, we will give participants different doses of the study drug to find out what the best dose is. In Part 2, we will only give participants the best dose of the study drug that is determined from Part 1.

Whether or not you are in Part 1 or Part 2 of the study will depend on when you join.

If you choose to join this study in either Part 1 or Part 2, you will:
- Be assigned to 1 of 3 possible study drug regimens
-- You will receive the study drug on its own; OR
-- You will receive the study drug in combination with daratumumab; OR
-- You will receive the study drug in combination with rituximab

Treatment cycles will last for 21 or 28 days. Your study doctor will evaluate how you are doing at the end of each cycle and determine whether or not you should continue.

Study Details

Full Title
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies
Principal Investigator
Cellular Therapy Specialist
Protocol Number
IRB: PRO00103294
NCT: NCT04136756
Phase I
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center